Breaking News
Get Actionable Insights with InvestingPro+: Start 7 Day FREE Trial Register here
Investing Pro 0
Ad-Free Version. Upgrade your Investing.com experience. Save up to 40% More details

Tenet Healthcare (THC) Q2 Earnings: What's In The Cards?

By Zacks Investment ResearchStock MarketsAug 01, 2019 11:25PM ET
www.investing.com/analysis/tenet-healthcare-thc-q2-earnings-whats-in-the-cards-200450085
Tenet Healthcare (THC) Q2 Earnings: What's In The Cards?
By Zacks Investment Research   |  Aug 01, 2019 11:25PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 

Tenet Healthcare Corporation (NYSE:THC) will report second-quarter 2019 results on Aug 5, after market close. In the last reported quarter, it delivered adjusted net earnings of 54 cents per share, outperforming the Zacks Consensus Estimate by 80%.

Let’s see how things are shaping up prior to this announcement:

We expect to see a year over year decline in revenues, due to lower number of licensed beds. Number of licensed beds are expected to decrease due to the company's divestitures. The consensus mark for the number of average licensed beds implies a 6.2% fall from the year-ago reported number. The consensus estimate for revenues is pegged at $4.4 billion, suggesting a dip of 0.5% from the year-ago period.

Revenues of Ambulatory Care and Conifer are likely to suffer in the second quarter.

The Zacks Consensus Estimate for earnings stands at 44 cents, indicating a decline of 10.2% from the prior-year reported figure.

Nevertheless, adjusted patient days are expected to improve marginally in the second quarter. The Zacks Consensus Estimate for the same indicates a 0.8% uptick from the year-earlier reported figure.

The second quarter is expected to take a beating due to increased malpractice, which was earlier projected by the company.

Overdependence on debt for growth-related investments might persistently increase the financial risk for Tenet Healthcare.

What the Quantitative Model States

Our proven model does not conclusively show that Tenet Healthcare is likely to beat on earnings this to-be-reported quarter. This is because the stock has the right combination of a positive Earnings ESP and a favorable Zacks Rank #1 (Strong Buy), 2 (Buy) or 3 (Hold) for this to happen, which is not the case here.

Earnings ESP: Tenet Healthcare has an Earnings ESP of 0.00%. This is because both the Most Accurate Estimate and the Zacks Consensus Estimate are pegged at 44 cents. You can uncover the best stocks to buy or sell before they are reported with our Earnings ESP Filter.

Zacks Rank: Tenet Healthcare carries a Zacks Rank #3, which increases the predictive power of ESP. However, the company’s 0.00% ESP makes surprise prediction difficult for the stock this reporting cycle.

We caution against Sell-rated stocks (#4 or 5) going into the earnings announcement, especially when the company is seeing negative estimate revisions.

Other Stocks to Consider

Some other stocks worth considering from the same space with the right combination of elements to also beat estimates this time around are as follows:

Opexa Therapeutics, Inc. (NASDAQ:ACER) is slated to release second-quarter earnings figures on Aug 12. The stock has an Earnings ESP of +29.61% and a Zacks Rank of 3. You can see the complete list of today’s Zacks #1 Rank stocks here.

Adverum Biotechnologies, Inc. (NASDAQ:ADVM) has an Earnings ESP of +14.75%. This #3 Ranked company is set to report second-quarter financial numbers on Aug 8.

BioLineRx Ltd. (NASDAQ:BLRX) is scheduled to announce second-quarter 2019 earnings performance on Aug 6. The stock has an Earnings ESP of +15.36% and is a Zacks #3 Ranked player.

Breakout Biotech Stocks with Triple-Digit Profit Potential

The biotech sector is projected to surge beyond $775 billion by 2024 as scientists develop treatments for thousands of diseases. They’re also finding ways to edit the human genome to literally erase our vulnerability to these diseases.

Zacks has just released Century of Biology: 7 Biotech Stocks to Buy Right Now to help investors profit from 7 stocks poised for outperformance. Our recent biotech recommendations have produced gains of +98%, +119% and +164% in as little as 1 month. The stocks in this report could perform even better.

See these 7 breakthrough stocks now>>



Adverum Biotechnologies, Inc. (ADVM): Free Stock Analysis Report

BioLineRx Ltd. (BLRX): Free Stock Analysis Report

Tenet Healthcare Corporation (THC): Free Stock Analysis Report

Opexa Therapeutics, Inc. (ACER): Free Stock Analysis Report

Original post

Zacks Investment Research
Tenet Healthcare (THC) Q2 Earnings: What's In The Cards?
 

Related Articles

Tenet Healthcare (THC) Q2 Earnings: What's In The Cards?

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email